Patient satisfaction with an injection device for multiple sclerosis treatment

Area of Science:

• Neurology
• Pharmacology
• Medical Devices

Background:

• Multiple sclerosis (MS) treatment often involves self-injection with interferon-beta-1a (IFN-beta-1a).
• Patient satisfaction and pain are critical factors influencing treatment adherence and quality of life.

Purpose of the Study:

• To develop and validate the MS Treatment Concerns Questionnaire (MSTCQ) for assessing treatment satisfaction specific to IFN-beta-1a injections.
• To evaluate the impact of a new injection device on patient-reported pain and treatment satisfaction.

Main Methods:

• The MSTCQ was developed and administered to patients switching from the Rebiject to the Rebiject II injection device.
• Pain assessments were conducted before and 3 months after the device change.

Main Results:

• The new device significantly improved MSTCQ scores for Injection System Satisfaction and Side Effects (except Flu-Like Symptoms).
• Statistically significant reductions in pain were observed post-device change (P < 0.0001).
• Effect sizes indicated clinically meaningful improvements in most measured scales.

Conclusions:

• Technologically advanced injection devices can lead to significant improvements in patient satisfaction and pain management for MS patients.
• The MSTCQ is a valuable tool for assessing patient concerns related to IFN-beta-1a injection therapy.